Leveraging Real-World Data for EMA Qualification of a Model-Based Biomarker Tool to Optimize Type-1 Diabetes Prevention Studies.
Saved in:
| Title: | Leveraging Real-World Data for EMA Qualification of a Model-Based Biomarker Tool to Optimize Type-1 Diabetes Prevention Studies. |
|---|---|
| Authors: | Podichetty JT; Critical Path Institute, Tucson, Arizona, USA., Lang P; Critical Path Institute, Tucson, Arizona, USA., O'Doherty IM; Critical Path Institute, Tucson, Arizona, USA., David SE; Critical Path Institute, Tucson, Arizona, USA., Muse RN; Critical Path Institute, Tucson, Arizona, USA., Karpen SR; Critical Path Institute, Tucson, Arizona, USA., Song LS; Critical Path Institute, Tucson, Arizona, USA., Romero K; Critical Path Institute, Tucson, Arizona, USA., Burton JK; Critical Path Institute, Tucson, Arizona, USA. |
| Corporate Authors: | Type-1 Diabetes Consortium (T1DC) |
| Source: | Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2022 May; Vol. 111 (5), pp. 1133-1141. Date of Electronic Publication: 2022 Mar 11. |
| Publication Type: | Journal Article; Research Support, U.S. Gov't, P.H.S.; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
